# Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT07159906** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 62 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Homoharringtonine
- **DRUG:** BCL-2 inhibitor
- **DRUG:** CD20 Antibody
- **DRUG:** Glucocorticoid (GC)

## Key facts

- **NCT ID:** NCT07159906
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159906, "Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07159906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*